Literature DB >> 20886240

Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials.

John T Maringwa1, Chantal Quinten, Madeleine King, Jolie Ringash, David Osoba, Corneel Coens, Francesca Martinelli, Jurgen Vercauteren, Charles S Cleeland, Henning Flechtner, Carolyn Gotay, Eva Greimel, Martin J Taphoorn, Bryce B Reeve, Joseph Schmucker-Von Koch, Joachim Weis, Egbert F Smit, Jan P van Meerbeeck, Andrew Bottomley.   

Abstract

BACKGROUND: The aim of this study was to determine the smallest changes in health-related quality of life (HRQOL) scores in a subset of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQ-C30) scales, which could be considered as clinically meaningful in patients with non-small-cell lung cancer (NSCLC).
METHODS: WHO performance status (PS) and weight change were used as clinical anchors to determine minimal important differences (MIDs) in HRQOL change scores (range, 0-100) in the EORTC QLQ-C30 scales. Selected distribution-based methods were used for comparison.
FINDINGS: In a pooled dataset of 812 NSCLC patients undergoing treatment, the values determined to represent the MID depended on whether patients were improving or deteriorating. MID estimates for improvement (based on a one-category change in PS, 5 - <20% weight gain) were physical functioning (9, 5); role functioning (14, 7); social functioning (5, 7); global health status (9, 4); fatigue (14, 5); and pain (16, 2). The respective MID estimates for deterioration (based on PS, weight loss) were physical (4, 6); role (5, 5); social (7, 9); global health status (4, 4); fatigue (6, 11); and pain (3, 7).
INTERPRETATION: Based on the selected QLQ-C30 scales, the MID may depend upon whether the patients' PS is improving or worsening, but our results are not definitive. The MID estimates for the specified scales can help clinicians and researchers evaluate the significance of changes in HRQOL and assess the value of a health care intervention or compare treatments. The estimates also can be useful in determining sample sizes in the design of future clinical trials.

Entities:  

Mesh:

Year:  2010        PMID: 20886240     DOI: 10.1007/s00520-010-1016-5

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  24 in total

1.  Defining clinically meaningful change in health-related quality of life.

Authors:  Ross D Crosby; Ronette L Kolotkin; G Rhys Williams
Journal:  J Clin Epidemiol       Date:  2003-05       Impact factor: 6.437

Review 2.  Optimistic biases about personal risks.

Authors:  N D Weinstein
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

3.  Commentary--goodbye M(C)ID! Hello MID, where do you come from?

Authors:  Holger J Schünemann; Gordon H Guyatt
Journal:  Health Serv Res       Date:  2005-04       Impact factor: 3.402

Review 4.  Measurement properties and interpretability of the Chronic respiratory disease questionnaire (CRQ).

Authors:  Holger J Schünemann; Milo Puhan; Roger Goldstein; Roman Jaeschke; Gordon H Guyatt
Journal:  COPD       Date:  2005-03       Impact factor: 2.409

Review 5.  Interpretation of quality of life changes.

Authors:  E Lydick; R S Epstein
Journal:  Qual Life Res       Date:  1993-06       Impact factor: 4.147

6.  What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592.

Authors:  David Cella; David T Eton; Diane L Fairclough; Philip Bonomi; Anne E Heyes; Cheryl Silberman; Michael K Wolf; David H Johnson
Journal:  J Clin Epidemiol       Date:  2002-03       Impact factor: 6.437

Review 7.  Methods to explain the clinical significance of health status measures.

Authors:  Gordon H Guyatt; David Osoba; Albert W Wu; Kathleen W Wyrwich; Geoffrey R Norman
Journal:  Mayo Clin Proc       Date:  2002-04       Impact factor: 7.616

8.  Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales.

Authors:  David Cella; David T Eton; Jin-Shei Lai; Amy H Peterman; Douglas E Merkel
Journal:  J Pain Symptom Manage       Date:  2002-12       Impact factor: 3.612

9.  Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire.

Authors:  M J Hjermstad; S D Fossa; K Bjordal; S Kaasa
Journal:  J Clin Oncol       Date:  1995-05       Impact factor: 44.544

10.  Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

Authors:  Egbert F Smit; Jan P A M van Meerbeeck; Pilar Lianes; Channa Debruyne; Catherine Legrand; Franz Schramel; Hans Smit; Rabab Gaafar; Bonne Biesma; Chris Manegold; Niels Neymark; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2003-11-01       Impact factor: 44.544

View more
  48 in total

1.  Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients' supportive care needs.

Authors:  Claire F Snyder; Amanda L Blackford; Jonathan Sussman; Daryl Bainbridge; Doris Howell; Hsien Y Seow; Michael A Carducci; Albert W Wu
Journal:  Qual Life Res       Date:  2014-11-15       Impact factor: 4.147

2.  "Important difference" for interpreting health-related quality of life outcome measures: important to whom?

Authors:  Jackson S Y Wu
Journal:  Support Care Cancer       Date:  2011-12-21       Impact factor: 3.603

3.  Minimal clinically important differences in the EORTC QLQ-BN20 in patients with brain metastases.

Authors:  Erin Wong; Liying Zhang; Marc Kerba; Palmira Foro Arnalot; Brita Danielson; May Tsao; Gillian Bedard; Nemica Thavarajah; Paul Cheon; Cyril Danjoux; Natalie Pulenzas; Edward Chow
Journal:  Support Care Cancer       Date:  2015-02-10       Impact factor: 3.603

4.  Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.

Authors:  Srinivas Raman; Keyue Ding; Edward Chow; Ralph M Meyer; Yvette M van der Linden; Daniel Roos; William F Hartsell; Peter Hoskin; Jackson S Y Wu; Abdenour Nabid; Rick Haas; Ruud Wiggenraad; Scott Babington; William F Demas; Carolyn F Wilson; Rebecca K S Wong; Liting Zhu; Michael Brundage
Journal:  Qual Life Res       Date:  2017-11-29       Impact factor: 4.147

5.  Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy.

Authors:  Srinivas Raman; Keyue Ding; Edward Chow; Ralph M Meyer; Abdenour Nabid; Pierre Chabot; Genevieve Coulombe; Shahida Ahmed; Joda Kuk; A Rashid Dar; Aamer Mahmud; Alysa Fairchild; Carolyn F Wilson; Jackson S Y Wu; Kristopher Dennis; Carlo DeAngelis; Rebecca K S Wong; Liting Zhu; Michael Brundage
Journal:  Qual Life Res       Date:  2016-05-02       Impact factor: 4.147

6.  Patient-Reported Outcomes with PD-1/PD-L1 Inhibitors for Advanced Cancer: A Meta-Analysis.

Authors:  Tomohiro F Nishijima; Shlomit S Shachar; Hyman B Muss; Kazuo Tamura
Journal:  Oncologist       Date:  2018-12-14

7.  Minimal clinically important differences in the brief pain inventory in patients with bone metastases.

Authors:  Karrie Wong; Liang Zeng; Liying Zhang; Gillian Bedard; Erin Wong; May Tsao; Elizabeth Barnes; Cyril Danjoux; Arjun Sahgal; Lori Holden; Natalie Lauzon; Edward Chow
Journal:  Support Care Cancer       Date:  2013-02-15       Impact factor: 3.603

8.  Confirmatory factor analysis of the Patient Assessment of Constipation-Symptoms (PAC-SYM) among patients with chronic constipation.

Authors:  Luca Neri; Paul Maurice Conway; Guido Basilisco
Journal:  Qual Life Res       Date:  2014-12-19       Impact factor: 4.147

9.  Prospective evaluation of anxiety, depression and quality of life in medically inoperable early stage non-small cell lung cancer patients treated with stereotactic ablative radiotherapy.

Authors:  Jacek Rutkowski; Magdalena Szymanik; Maciej Blok; Joanna Kozaka; Renata Zaucha
Journal:  Rep Pract Oncol Radiother       Date:  2017-04-21

10.  Can Methods Developed for Interpreting Group-level Patient-reported Outcome Data be Applied to Individual Patient Management?

Authors:  Madeleine T King; Amylou C Dueck; Dennis A Revicki
Journal:  Med Care       Date:  2019-05       Impact factor: 2.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.